EU Accepts Aspen Price Commitments
Reductions On Oncology Drugs Offered To Settle Price Gouging Claims
Commitments offered by Aspen Pharmacare last year to settle price-gouging allegations over six oncology drugs have been accepted by the European Commission.
You may also be interested in...
After the European Commission adopted a preliminary assessment that Aspen Pharmacare “may have abused its dominant position by imposing unfair prices” for six mature oncology brands, the South African firm has outlined multiple commitments that would bring to a close a three-year Commission investigation across the EEA if adopted.
The UK’s CMA has issued fines of nearly £2.3m after formally concluding that three firms participated in illegal arrangements over fludrocortisone that violated competition law.
Aspen has agreed to pay the National Health Service £8m following an investigation by the Competition and Markets Authority.